News
In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback